Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

How Pro Medicus (ASX:PME) is expanding its US hospital contracts after record FY26 earnings

For the financial year ended 30 June 2026, Pro Medicus reported revenue of AUD 261.7 million, representing growth of 22.9% compared with FY25.

Sonal Goyal | 11 November 2026

ASX today: BlinkLab (ASX:BB1) reports early SHANK2 autism study results ahead of schedule

According to BlinkLab's announcement on 11 November 2026, 20 people were recruited for the study, comprising nine with a SHANK2 mutation and 11 unaffected siblings. Of those, eight SHANK2 participants and 10 siblings completed the 15-minute smartphone assessment. Two people could not complete testing …

Sonal Goyal | 11 November 2026

ASX today: Immutep (ASX:IMM) reports 81.1% 12-month disease-free survival in sarcoma trial

EFTISARC-NEO is testing efti in combination with KEYTRUDA (pembrolizumab) and radiotherapy as a neoadjuvant treatment, meaning it is given before an operation to remove the tumour. According to Immutep's release dated 11 November 2026, the survival data come from 38 evaluable patients with a …

Sonal Goyal | 11 November 2026

Singular Health Group (ASX:SHG): How Is 3DICOM Progressing From Regulatory Clearance to Adoption?

Singular Health Group Limited (ASX:SHG) listed an announcement on 13 January 2026 confirming US Food and Drug Administration 510(k) clearance for 3DICOM MD Cloud. The clearance is relevant to the specific product and permitted regulatory pathway described in that filing. It should not be …

Aditi Sarkar | 11 November 2026

BlinkLab Limited (ASX:BB1) Reports Positive SHANK2 Autism Biomarker Results, Validating Smartphone Neurometric Platform

Twenty participants were recruited through the SHANK2 Foundation: nine individuals with a SHANK2 mutation and eleven unaffected siblings, of whom eight and ten respectively completed the 15-minute smartphone assessment. These were compared against a matched community group of 99 participants using the same experimental …

Aditi Sarkar | 11 November 2026

What Telix Pharmaceuticals' ITM Merger and Pixclara Approval Mean for the ASX 200 Radiopharmaceutical Group (ASX:TLX)

Two items stand out in the 20 October release. The first is the proposed merger with ITM, a radiopharmaceutical group focused on therapy. A further contingent payment of up to US$700 million is linked to regulatory and commercial milestones for ITM-11. Closing requires TelixShareholderapproval, …

Sonal Goyal | 11 November 2026

What Sonic Healthcare's (ASX:SHL) FY26 Result and FY27 Guidance Say About Growth Through Acquisition

Sonic is a global medical diagnostics company. Its core is clinical pathology (laboratory testing ordered by doctors), supplemented by radiology and other medical services in several countries. Revenue arises from testing volumes and the prices or fees paid by government health programs, insurers and …

Sonal Goyal | 11 November 2026

How Ramsay Health Care (ASX:RHC) Is Preparing to Separate Ramsay Santé After a More encouraging FY26

Ramsay operates private hospitals and related services in three regions. Australia runs private acute hospitals, whereRevenuedepends on patient volumes, the doctors who admit patients (visiting medical officers) and funding from private health insurers. The United Kingdom includes Ramsay UK, which treats NHS and private …

Sonal Goyal | 11 November 2026

Why nib Holdings (ASX:NHF) Is Selling Its Travel Business and Raising Its Payout Target

The travel sale is the key structural change. According to the company, the sale of the nib Travel businesses is expected to complete in 1H27 and to deliver about A$97 million of net cash, of which about A$24 million funds a special dividend. The …

Sonal Goyal | 11 November 2026

What Neuren Pharmaceuticals' (ASX:NEU) First Dividend Means for Its DAYBUE Royalty Model

DAYBUE royalty income: US$23.3 million, up 29 per cent in US dollars.

Sonal Goyal | 11 November 2026
Support

Hi! How can we help you today?

Loading…